Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Taxane-containing chemotherapy regimens

Statements of evidence

STATEMENTS LEVEL OF EVIDENCE24 REFERENCE
Adjuvant chemotherapy in women with early(operable)breast cancer:
Overall and disease free survival benefit
Inclusion of a taxane in adjuvant chemotherapy regimens improves disease-free and overall survival compared to non-taxane containing regimens I Cochrane2
Type of taxane
There are similar benefits for disease-free and overall survival for taxane regimens containing either paclitaxel or docetaxel I Cochrane2
Schedule and duration of administration
There are similar benefits for disease-free survival and overall survival for women treated with a taxane-containing regimen regardless of whether the anthracycline is administered sequentially or concurrently with the taxane I Cochrane2
There are similar benefits for disease-free and overall survival for women treated with a taxane-containing regimen when adding or substituting a taxane as part of a chemotherapy regimen I Cochrane2

There are similar benefits for disease-free and overall survival for women treated with a taxane-containing regimen:

  • which is of the same duration as the non-taxane containing regimen, or
  • which is of longer duration than the non-taxane containing regimen
   
Lymph node status

There are similar benefits for disease-free survival and overall survival between studies that include women with node positive disease only and studies that include women with node positive or node negative disease

No studies have reported results on the use of taxane-containing regimens in women with node negative disease only

I Cochrane2
Hormone receptor status

There was no level I evidence reporting efficacy of taxanes according to hormone receptor status

Results from individual randomised controlled phase III studies are conflicting and no recommendation can be made according to hormone receptor status

Adverse events

Taxane-containing regimens are associated with an increased incidence of febrile neutropenia compared with non-taxane-containing chemotherapy regimens

The increase in febrile neutropenia is most pronounced in concurrent anthracycline and taxane regimens

I Cochrane2

Taxane-containing chemotherapy regimens are associated with decreased incidence of nausea and vomiting compared with a non-taxane containing chemotherapy regimens

The decrease in nausea and vomiting is most pronounced where the inclusion of a taxane has resulted in lower doses of anthracycline

I Cochrane2
Taxane-containing regimens may be associated with a reduction in cardiac toxicity compared with non taxane-containing chemotherapy regimens, where the inclusion of a taxane has resulted in lower cumulative anthracycline exposure I Cochrane2
Neoadjuvant chemotherapy in women with early(operable)breast cancer:

One study reported that the inclusion of a taxane in a neoadjuvant chemotherapy regimen significantly increased pathological and clinical complete response rates compared to a non-taxane-containing chemotherapy regimen

There is currently insufficient evidence to determine the optimal role of taxane-containing regimens in neoadjuvant chemotherapy treatment

II NSABP B2716

Published using CeCC Docbook Manager